Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Dare Bioscience Inc (DARE)

Dare Bioscience Inc (DARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 122,003
  • Shares Outstanding, K 70,522
  • Annual Sales, $ 0 K
  • Annual Income, $ -27,400 K
  • 60-Month Beta 1.69
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 12.90
Trade DARE with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.12
  • Number of Estimates 3
  • High Estimate -0.01
  • Low Estimate -0.17
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6200 +6.79%
on 09/13/21
1.8300 -5.46%
on 09/02/21
+0.0800 (+4.85%)
since 08/24/21
3-Month
1.4200 +21.83%
on 07/27/21
2.4500 -29.39%
on 07/07/21
+0.2700 (+18.49%)
since 06/24/21
52-Week
0.9447 +83.13%
on 10/28/20
3.8500 -55.06%
on 01/20/21
+0.7500 (+76.53%)
since 09/24/20

Most Recent Stories

More News
Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy

Dare Bioscience (DARE) starts a phase I/II study to evaluate DARE-VVA1 to treat moderate to severe vulvar and vaginal atrophy.

REGN : 638.90 (-1.18%)
VRTX : 183.61 (-0.80%)
RGEN : 323.26 (-0.29%)
DARE : 1.7300 (-1.70%)
Dare Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy

Investigational therapy for women who cannot, or should not, take supplemental estrogen

DARE : 1.7300 (-1.70%)
Dare Bioscience to Present at the 2021 Cantor Virtual Global Healthcare Conference

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the Virtual Global...

DARE : 1.7300 (-1.70%)
Dare Bioscience to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will deliver a company presentation...

DARE : 1.7300 (-1.70%)
Dare Bioscience to Participate in Panel Discussion at Women's Health Innovation Summit

The discussion, Women's Health Case Study: Optimizing Study Enrollment During the COVID-19 Pandemic, will review the DARE-BVFREE Phase 3 study that was successfully initiated and completed during 2020

DARE : 1.7300 (-1.70%)
Dare Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today reported financial results for the quarter ended June 30, 2021 and provided a company update.

DARE : 1.7300 (-1.70%)
Dare Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis

-- Six-month priority review granted for DARE-BV1 with PDUFA target action date set for December 7, 2021.

DARE : 1.7300 (-1.70%)
Dare Bioscience to Host Second Quarter 2021 Financial Results and Company Update Conference Call and Webcast on August 12, 2021

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 12, 2021,...

DARE : 1.7300 (-1.70%)
Dare Bioscience to Present at the 2021 Controlled Release Society Virtual Annual Meeting to be held July 25-29, 2021

Presentation will highlight the positive topline results from the DARE-BVFREE Phase 3 randomized, double-blinded, placebo-controlled clinical trial evaluating Dare's product candidate DARE-BV1 in women...

DARE : 1.7300 (-1.70%)
Thinking about buying stock in Verb Technology, Ericsson, Dare Bioscience, ContextLogic, or Climate Chang Cris Real Impct I Acq Corp?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VERB, ERIC, DARE, WISH, and EVGO.

DARE : 1.7300 (-1.70%)
ERIC : 11.61 (+2.11%)
EVGO : 8.76 (+1.27%)
VERB : 1.7900 (-3.76%)
WISH : 6.02 (-1.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Dare Bioscience, Inc. is a healthcare company. It involved in the development and commercialization of products in women's reproductive health. Dare Bioscience, Inc., formerly known as Cerulean Pharma Inc., is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 1.8098
2nd Resistance Point 1.7899
1st Resistance Point 1.7599
Last Price 1.7300
1st Support Level 1.7100
2nd Support Level 1.6901
3rd Support Level 1.6601

See More

52-Week High 3.8500
Fibonacci 61.8% 2.7402
Fibonacci 50% 2.3973
Fibonacci 38.2% 2.0545
Last Price 1.7300
52-Week Low 0.9447

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar